NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

NCT04727723

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Interventions: Lutathera®

Countries: Italy

This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Written informed consent must be obtained prior to any data collection.
* Patients must be diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic-neuroendocrine tumour (GEP-NET).
* Aged ≥18 years.
* Patients must be naïve to treatment with Lutathera® at enrolment.

Exclusion Criteria:

* Participation in a current or prior investigational study within 30 days preceding enrolment or within 5 half-lives of the investigational product, whichever is longer.

Locations (18)

Alessandria, Italy
Bologna, Italy
Brescia, Italy
Cona, Italy
Florence, Italy
Latina, Italy
Meldola, Italy
Messina, Italy
Milan, Italy
Naples, Italy
Negrar, Italy
Padova, Italy
Pisa, Italy
Reggio Emilia, Italy
Rionero in Volture, Italy
Roma, Italy
Rozzano, Italy
Torino, Italy